Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIG-1 Trial in Acute Myeloid Leukemia
NCT02416388Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Jan 2015
- Primary completion
- Jul 2025
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of idarubicin, cytarabine, mycophenolic acid, vosaroxin, dexamethasone in acute myeloid leukemia (AML), sponsored by Centre Hospitalier Universitaire d'Angers. Started Jan 2015; status: recruiting.
02
Drugs
idarubicincytarabinemycophenolic acidvosaroxindexamethasone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02416388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02416388.